We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Bydureon Suffers Another Setback With Complete Response Letter
Bydureon Suffers Another Setback With Complete Response Letter
October 22, 2010
Eli Lilly, Amylin and Alkermes will need to conduct an additional clinical trial for their once-weekly diabetes drug Bydureon after receiving a second complete response letter from the FDA.